Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Intangibles: 2018-2024

Historic Intangibles for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $23.9 million.

  • BridgeBio Pharma's Intangibles rose 17.41% to $28.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.8 million, marking a year-over-year increase of 17.41%. This contributed to the annual value of $23.9 million for FY2024, which is 9.09% down from last year.
  • Per BridgeBio Pharma's latest filing, its Intangibles stood at $23.9 million for FY2024, which was down 9.09% from $26.3 million recorded in FY2023.
  • BridgeBio Pharma's Intangibles' 5-year high stood at $44.9 million during FY2021, with a 5-year trough of $23.9 million in FY2024.
  • Its 3-year average for Intangibles is $26.3 million, with a median of $26.3 million in 2023.
  • Data for BridgeBio Pharma's Intangibles shows a maximum YoY crashed of 36.10% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows BridgeBio Pharma's Intangibles stood at $44.9 million in 2021, then plummeted by 36.10% to $28.7 million in 2022, then fell by 8.33% to $26.3 million in 2023, then fell by 9.09% to $23.9 million in 2024.